STS Flashcards

1
Q

What are some factors that can influence local recurrence of STS?

A
  1. tumour size
  2. tumour infiltration
  3. degree of surgical resection
  4. tumour grade
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which is the most important factor for risk of metastasis for STS?

A

tumour grade

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which breeds may be predisposed to FSA?

A

Golden and Doberman pinchers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some interesting features of FSA?

A
  • tend to be in younger dogs (vs the general population for STS)
  • more likely to recur after incomplete resection
  • may have more mitotic counts versus other STS
  • but are also more likely to be low grade
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which breeds may be predisposed to pleomorphic undifferentiated sarcoma?

A
  • flat coated retriever
  • Rotties
  • Goldens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which IHC can be used for undifferentiated pleomorphic sarcoma?

A

vimentin (+)
CD18 (-)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What’s the biological behaviour of undifferentiated pleomorphic sarcoma in dogs?

A

Aggressive.
- Often found with metastasis to SQ, LNs, liver and lungs
- 1 study reported MST of 61 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Where are the most common locations for undifferentiated pleomorphic sarcoma?

A
  • trunk
  • pelvic limbs
  • spleen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What markers are expressed by periocytes? myoperiocytes? smooth muscles?

A

-Periocytes: vimentin, variable degree of smooth muscle actin
- myoperiocytes: (also) desmin, calponin
- smooth muscles: smoothlin, heavy caldesmon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What’s the general cause of death for peripheral nerve sheath tumour?

A

patients generally die from the local disease rather than metastasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What’s the outcome for peripheral nerve sheath tumour amendable for amputation?

A
  • if completely removed, MST = 2227 days (6y), which is significantly better than incomplete removal (487 days, 1.3y). The overall MST = 1303 days (3.5y)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What’s the outcome of brachial plexus tumour treated with SRT?

A
  • PFI = 240 days
  • OST = 371 days
  • 90% of the dogs had disease progression
  • complete or partial neurological resolution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which IHC stains can help to differentiate between well-differentiated liposarcoma and de-differentiated liposarcoma?

A

MDM2 and CDK4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What’s the outcome of surgical removal of liposarcoma?

A
  • complete removal: MST = 1188 days (3.25y)
    -marginal surgery: MST = 649 days (1.7y)
  • Incisional biopsy: MST = 183 days (6 months)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What it’s the prognostic value of histo subclassification of rhabdmyosarcoma?

A
  • Botryoid tumours: grape-like clusters, more commonly found in the urinary bladder, may be more female, large breeds (St. Bernard). Metastatic rate = 27%
  • Embryonic tumours: tend to be in younger dogs, head/neck/ retrobulbar. Metastatic rate = 50%. MST for young dogs = 2 months
  • Alveolar tumours - also has a met rate of 50%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What’s the outcome of dogs with lymphangiosarcoma treated with Sx +/- RT versus no treatment?

A
  • Sx: MST = 487 days (16m)
  • Sx + RT: ST = 547 days (18m)
  • No Tx: MST = 168 days
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What’s the reported outcome of splenic mesenchymoma?

A

MST = 1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What’s the diagnostic yield of FNA for STS?

A

63-97%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What’s the dis-concordance rate of pre-op biopsy vs post-op histology?

A

41%:
29% underestimated, 12% overestimated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What’s the recurrence rate of incompletely removed grade I, grade II and grade III STS?

A
  • Grade 1 = 7%
  • Grade 2 = 34%
  • Grade 3 = 75% (3/4 dogs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Generally, what is the recurrence rate of low-grade STS?

A
  • PWT: 11%, 18-20% (60-63% were incompletely removed in the entire sample)
  • 28% (when <10% resected with 3cm margins)
  • 21% (only 5% had wide surgical margins in the entire sample)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are some prognostic factors predictive of local recurrence after surgery?

A
  • large primary tumour size (>5cm)
  • high grade (III)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What’s staging surgery for STS?

A

Can be done if the initial STS was incompletely removed. Aim for <1cm lateral margin around the scar to determine if further (larger) resection margin is needed.
- One study found only 22% of 39 incompletely removed STS had residual disease on staging surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What’s the outcome of incompletely removed STS treated with metronomic cyclophosphamide with piroxicam?

A

The DFI is significant longer in treated vs control group (but the control group had very high rate of progression)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
What's the outcome of electrochemotherapy for incompletely removed STS using bleomycin?
22 dogs - local recurrence rate = 36% - mean time to recurrence = 730 days (2y) - wound dehiscence noted in 14% Another study with 52 dogs - RR and DFI were similar between intra-op and post-op ECT (23% and 25%, 81.5 and 243 days, respectively - 2 CR, 1 PR, 1 SD (with ECT alone)
26
What's the recurrence rate and time to recurrence for Sx, Sx + RT, or Sx+ intralesional chemo for STS?
27
What's the general survival rate of STS treated with Sx and CFRT?
- overall MST = 2270 days (6y) - 75% survival rate at 5y - DFI 412 days to >798 days (1-2+ years)
28
What's the general survival rate of STS treated with Sx and hypofractionated RT?
- local recurrence rate 18-21% (small, low grade STS) - PFI: 698 days + (~2y+) Outcome significantly influenced by tumour grade - Grade I PFI = 5y - Grade II PFI = 1.5y - Grade III PFI = 9 m (MST = 940 [2.5y])
29
What's the outcome for CFRT to measurable STS?
Control rate @ 1y = 50%, @ 2y = 30%
30
What's the outcome of hypofractionated RT to measurable STS?
RR = 46-50%, majority = stable disease - mPFI: 155-419 days (5-14 months) - MST: 206-513 days (7-17 months) Limbs do better than head/trunk
31
What's the role of adjuvant the chemotherapy for canine STS?
Controversial - median time to metastasis 230-365 days - no significant difference between Sx vs Sx + doxorubicin for grade III STS
32
What's the metastatic rate of canine STS?
Grade 1: 0-13% Grade 2: 7-27% Grade 3: 22-44%
33
What's the role of metronomic chemotherapy for canine STS?
may be beneficial to reduced local recurrence - did improve ST in PRT with gross STS - cyclophosphamide at 15mg/m2 daily can suppress Tregs
34
What's the outcome of intralesional chemotherapy for canine STS?
- local recurrence rate 17-31% (more likely with grade III) - wound complication = common --> 47-84%
35
What's the reported MST for Sx alone and Sx + RT for canine STS:
Sx: MST = 1013-1796 days (2.8-5y) Sx + RT: MST = 2270 days (6y) but the majority of the patients (2/3) will die of unrelated causes, so many MST not reached
36
What's the outcome between wide surgical vs marginal removal? Complete margin vs incomplete margin?
Wide - MST = 1306 (3.5y) Marginal - MST = 264 days (8m) Complete margin - MST = >1306 days (3.5y+) Incomplete margin - MST = 657 days (1.8y)
37
What are some histological prognostic factors for canine STS?
- mitotic count: > 20 = 5x more likely to die - tumour grade: MST 940 days (2.5y) for grade III Sx + CFRT - AgNOR - Ki67
38
What's the time to recurrence for marginally removed/ non referral vs wide resection/ referral?
Marginally removed: 79 days Non-referral: 69 days Wide resection: 325-419 days Referral: 274 days
39
With the recommended surgical margins (5cm lateral, 2 fascial planes deep), what's the rate of complete excision and local recurrence rate for FISS?
97% complete resection recurrence at 3y is 14%
40
What's the outcome of pre-op RT for local control for FISS?
- local tumour recurrence rate 40-45% - median time to recurrence 398-584 days (1-1.5y) - complete resection prolong DFI but not recurrence rate
41
What's the outcome of post-op RT for FISS?
similar to pre-op - Local recurrence rate: 28-41% - DFI: 13-37 months
42
What's the outcome of post-op PRT for FISS?
MST 24 months
43
What's the general outcome of Sx and RT for FISS?
- MST 600-1307 (1.5-3.5y) - Local recurrence rate: 28-45%
44
What's the outcome of RT to gross disease for FISS?
- one study used liposomal DOX as a RT senitizer --> 7/10 PR, 2/10 CR, but short lived (117 days) - another study found PFI of 4m and MST = 7m
45
What's the outcome of SRT to gross disease for FISS?
PFI = 242 days MST = 301 days 3/11 CR; 5/11 PR
46
What's the role of chemotherapy for FISS?
- undefined - typically use doxorubicin - can prolonged survival time, if there is gross disease still
47
What's the metastatic rate and median time to metastasis for FISS?
- 0-26% - DFI: 265-309 days
48
What's the effect of chemo on curative intent Sx+ RT for FISS?
may not be beneficial for survival time, but could prolong the time to recurrence
49
What's the theoretical benefit of using TKI?
- They can target the PDGFR - no clinical beneficial results at current dosing
50
What's the outcome for ETC for FISS?
Pre-op: DFI 19m Intra-op: DFI 12m No ETC: DFI 4m metastatic rate only 1.7% another study: - post-op: recurrence rate = 29%
51
Which immunotherapy holds potential for FISS?
IL-2, can significantly reduce the frequency of relapse
52
In general, what's the local recurrence rate (complete vs. incomplete) for FISS?
Complete: 14-22% Incomplete: 58-69%
53
In general, what's the local recurrence rate for FISS with Sx and RT?
28-45% DFI = 13-37m
54
What's the metastatic rate of FISS based on the grade?
Grade 1: 0-17% Grade 2: 15-19% Grade 3: 22-100%
55
Generally, what's the survival of FISS treated with Sx?
MST 804-901+ days (2-2.5 y) less aggressive Sx: MST = 395-608 days (1-1.5y)
56
Generally, what's the survival of FISS treated with Sx and RT?
MST = 520 - 1307 days (1.5-3.5y)
57
What's the MST for FISS with distant metastasis versus no?
with mets: MST = 165-388 days no mets: MST = 929-1528 days (2.5-4y)
58
What's the 3-2-1- rule?
- If the mass is still present after 3m, - > 2cm - or still growing after 1m
59
What's the most common visceral STS?
- leiomyosarcoma - most common location = spleen
60
What's the local recurrence and metastatic rate of visceral STS after surgery?
- local recurrence rate = 4.7% Metastatic rate = 23.8% on presentation, 40% at necropsy
61
What's a prognostic factor for visceral STS?
MI > = to 9 had significantly shorter survival (MST 269 days).
62
How does the MST differ with different grades of STS in the viscera?
The MST for grade I STSs was not reached, was 589 days for grade II and 158 days for grade III.
63
What's the % of recurrence based on a meta analysis for surgically removed canine STS?
- 9.8% recur even if completely removed - 33.3% recur with incomplete margin
64
What's the outcome of canine splenic stromal sarcoma post splenectomy?
in 32 dogs - 22 developed metastasis - mitotic count = prognostic in multivariate - adjuvant chemo did not significantly impact metastasis or ST
65
What's the outcome of using carboplatin for gross mesenchymal tumour (none oseous)?
ORR: 14.2% (4/28) --> only seen in HSA Median PFI: 42 days
66
What histological parameters were associated with metastasis and tumour related death for canine smooth muscle tumours?
- Mitotic count - Ki67 - Necrosis - Smooth muscle tumours were most commonly found in the female genital tract, alimentary tract, and soft tissue. - mostly benign